NEWAMSTERDAM PHARMA CO NV
NAMSNASDAQ🏆 #1754 by market capEarnings Nov 11 · PreUS Equity
$20.76▼ $0.31 (−1.47%)
🌙 After hours$20.76▲ 0.00%Regular close · extended-hours price shownTrack NAMS
Get earnings, price moves & breaking news on Telegram
24h▼ 1.5%
7d▲ 5.4%
14d▲ 4.7%
30d▼ 14.7%
ytd▼ 40.8%
1y▼ 46.5%
🏦Market Cap
$2.48B
Small Cap
📈Revenue Growth (YoY)
-88.9%
Declining
📊Gross Margin
—
💵FCF Margin
1648.5%
Strong
⚖️P/S Ratio
353.7x
Expensive
Otter Score
—
Insufficient data
NEWAMSTERDAM PHARMA CO NV
NAMSAnalyst Ratings
Price
$20.76
Total
10
Raised
0
Lowered
0
Avg PT
$51.33
H / L
$58 / $45
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
RBC Capital | Reiterated | Outperform | 2026-10-05 | $51.00 | +145.70% |
HC Wainwright & Co. | Reiterated | Buy | 2026-09-08 | — | — |
Guggenheim | Reiterated | Buy | 2026-02-19 | $45.00 | +116.80% |
Needham | Reiterated | Buy | 2026-02-18 | $36.00 | +73.40% |
Stifel | Reiterated | Buy | 2025-12-16 | — | — |
Goldman Sachs | Reiterated | Neutral | 2025-12-02 | $37.00 | +78.20% |
Citigroup | Reiterated | Buy | 2025-10-17 | — | — |
Scotiabank | Reiterated | Sector Outperform | 2025-02-27 | — | — |
Piper Sandler | Reiterated | Overweight | 2024-09-23 | $37.00 | +78.20% |
Credit Suisse | Reiterated | Outperform | 2023-04-03 | — | — |
Institution
RBC Capital
Reiterated · Outperform · 2026-10-05
$51.00
+145.70%
HC Wainwright & Co.
Reiterated · Buy · 2026-09-08
—
—
Guggenheim
Reiterated · Buy · 2026-02-19
$45.00
+116.80%
Needham
Reiterated · Buy · 2026-02-18
$36.00
+73.40%
Stifel
Reiterated · Buy · 2025-12-16
—
—
Goldman Sachs
Reiterated · Neutral · 2025-12-02
$37.00
+78.20%
Citigroup
Reiterated · Buy · 2025-10-17
—
—
Scotiabank
Reiterated · Sector Outperform · 2025-02-27
—
—
Piper Sandler
Reiterated · Overweight · 2024-09-23
$37.00
+78.20%
Credit Suisse
Reiterated · Outperform · 2023-04-03
—
—
One row per institution · price target from the firm's latest published target
StockOtter · stockotter.space